Whirlpool Corporation Welcomes Judith Buckner to Board of Directors
'Judith is a highly respected leader who knows how to create a positive impact in all aspects of the business and we are excited to have her joining our board,' said Marc Bitzer, chairman and CEO of Whirlpool Corporation. 'Her vast experience in the kitchen category will be an incredible asset as Whirlpool Corporation continues to focus on improving life at home for consumers around the world.'
Buckner was named president of Reynolds Cooking & Baking in 2022, having previously served as president of the Presto Products business unit of Reynolds Consumer Products, Inc., as well as the senior vice president of business transformation at Reynolds Consumer Products, Inc. and the vice president of operations and engineering for the Hefty Waste Bags & Food Bags. Buckner joined Reynolds Consumer Products, Inc. in 2000 as an engineering manager and has held various positions of increasing responsibility in manufacturing, operations and engineering.
Buckner graduated from Purdue University with a degree in chemical engineering.
About Whirlpool CorporationWhirlpool Corporation (NYSE: WHR) is a leading home appliance company, in constant pursuit of improving life at home. As the only major U.S.-based manufacturer of kitchen and laundry appliances, the company is driving meaningful innovation to meet the evolving needs of consumers through its iconic brand portfolio, including Whirlpool, KitchenAid, JennAir, Maytag, Amana, Brastemp, Consul, and InSinkErator. In 2024, the company reported approximately $17 billion in annual sales – close to 90% of which were in the Americas – 44,000 employees, and 40 manufacturing and technology research centers. Additional information about the company can be found at WhirlpoolCorp.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
American Express Leadership Academy Returns to London with Dior Creative Director Jonathan Anderson
The four-day program, created in partnership with Common Purpose, will feature Anderson and a dynamic lineup of programming for nonprofit leaders from 24 countries LONDON, July 3, 2025 /PRNewswire/ — American Express today announced that Jonathan Anderson, acclaimed creative director of Dior, former creative director of Loewe, and founder of JW Anderson, will join the 2025 American Express Leadership Academy in London to address nonprofit leaders on how to lead through innovation and drive impact. Anderson's appearance marks a major milestone for the Academy, introducing one of the most influential voices in global design and creative leadership to nonprofit leaders participating in the London program. Anderson will be in conversation with Alexander Fury, fashion features director at large for Another Magazine and menswear critic at Financial Times. Hosted in partnership with Common Purpose, the American Express Leadership Academy's London program will welcome 78 nonprofit leaders from two dozen countries in Europe, the Middle East, and Africa in early July. Founded in 2007, the Academy is designed to build the personal, business, and communication skills of leaders through multi-day in-person and virtual programming. Since its launch, American Express has invested approximately $100 million in the Academy and has helped more than 165,000 leaders around the world reach their potential. 'For 18 years, the American Express Leadership Academy has been bringing together nonprofit leaders to build their leadership skills and strategic mindset to drive meaningful change,' said Jennifer Skyler, Chief Corporate Affairs Officer at American Express. 'As a visionary in the fashion world, Jonathan Anderson will share his philosophy on leading global creative brands with creativity, purpose, and resilience, as we continue to gather bold thinkers across sectors to learn from one another and accelerate their global impact.' This year's London program will feature a robust schedule of learning opportunities, including storytelling workshops, immersive visits with other nonprofits, and group projects on topics like building an innovative mindset. As the final stop for this year, the American Express Leadership Academy will head to New York in November. To apply for the 2025 Americas cohort or register for future cohorts around the world, click here. ABOUT AMERICAN EXPRESS American Express (NYSE: AXP) is a global, premium payments and lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services and experiences that enrich lives and build business success. Founded in 1850 and headquartered in New York, American Express' brand is built on trust, security, and service, and a rich history of delivering innovation and Membership value for our customers. With a hundred million merchant locations on our global network in over 200 countries and territories, we seek to provide the world's best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations. For more information about American Express, visit and MEDIA CONTACT: Jessica Logo – View original content:
The Sun
8 hours ago
- The Sun
Cushman & Wakefield and Corenet Global Release New Survey Results On 'What Occupiers Want'
HONG KONG SAR - Media OutReach Newswire - 2 July 2025 - Cushman & Wakefield (NYSE: CWK), in partnership with CoreNet Global, the global professional association for corporate real estate, has released new survey results revealing how corporate real estate (CRE) priorities are evolving in response to cost pressures, shifting organizational models, a stabilizing office footprint, and the growing demand for workplace flexibility and service. Findings from the What Occupiers Want 2025 survey—reflecting the views of CRE decision-makers across the Americas (52%), EMEA (34%) and APAC (14%)—highlight an industry at a strategic crossroads, as companies balance traditional cost control measures with new imperatives around talent, culture, and portfolio agility. The views represent approximately 8.1 million employees globally and approximately 340M square feet of floor area. 'The survey shows that while cost discipline remains essential, organizations are increasingly recognizing that real estate decisions directly impact employee experience, engagement, and overall business performance,' said Despina Katsikakis, Global Lead, Total Workplace Consulting at Cushman & Wakefield. 'This marks a critical opportunity for CRE leaders to shape strategies that deliver both financial and workforce value.' Cost Still Reigns, but Uncertainty Dominates Decision-Making Cost control remains the top driver of corporate real estate decisions globally, as CRE leaders face continued pressure to reduce or optimize spending. Financial KPIs—particularly cost, efficiency, and space utilization—still dominate strategy. However, uncertainty looms large. Political instability, changing workplace behaviors, and unclear ROI metrics have left many organizations hesitant to act boldly. Compounding this, environmental, social, and governance (ESG) priorities—once on the rise—have slipped back to pre-2021 levels in global importance, though they remain a top concern in EMEA and APAC regions. CRE Organizational Models Are Evolving—And Metrics Must Keep Pace One of the report's most striking findings: nearly one-third (29%) of companies that recently changed their CRE reporting structure now have real estate teams reporting to Human Resources. 'This shift highlights a growing understanding that corporate real estate is about people, culture, and experience—not just space and cost,' said Katsikakis. 'But to make this evolution meaningful, organizations need new performance metrics that link workplace investments to employee experience, engagement, and productivity—not just financial outcomes.' Despite these organizational changes, most companies continue to rely heavily on traditional financial measures. The report calls for a balanced scorecard approach that bridges the gap between cost control and workforce impact. Downsizing Has Peaked as Occupiers Stabilize Portfolios After several years of footprint reduction, the era of mass downsizing appears to be over. Only 32% of companies plan further space cuts, while 1 in 8 occupiers plan to expand their footprint. Meanwhile, average office lease sizes have grown by 13% since 2023. Office utilization rates are stabilizing as well, with global occupancy levels settling between 51% and 60%—still below pre-pandemic norms but rising steadily as more firms implement structured return-to-office policies. Landlords Must Step Up as the Office Becomes a Service Tenants are demanding more from their landlords—85% of occupiers now expect landlords to provide enhanced amenities, services, and workplace experiences, and nearly half (46%) are willing to pay a premium for these upgrades. Top-tier office space commands a nearly double-digit rental premium as a result. Yet there remains a gap between expectation and delivery: only 60% of employees believe their current workplace fully supports collaboration, relationships, and culture-building—the very elements that draw people back to the office. Flexible Location Strategies Are the New Talent Imperative Flexible hiring practices are now standard, with 61% of companies adapting their real estate strategies to access diverse talent pools across multiple geographies. Regional trends show varied approaches: • In the Americas, hybrid and country-level hiring dominate. • EMEA firms favor selective global hiring where presence already exists. • APAC leads in expanding remote hiring options. Technology talent remains in high demand, particularly in APAC, where growth outpaces that of the Americas and EMEA. The 2025 What Occupiers Want survey reveals a CRE industry in transition: while cost pressures remain paramount, leading organizations are redefining value beyond financial savings. 'To drive meaningful impact, CRE leaders must champion new, integrated performance frameworks that reflect the true business value of the workplace,' said Katsikakis. 'Real estate decisions are no longer just about the bottom line—they're about workforce performance, culture, and competitive advantage.' Spotlight: Chinese Mainland On the Chinese mainland, occupier strategies are aligning with the broader Asia Pacific trends – but with distinct local drivers. Companies continue to prioritize cost optimization and footprint efficiency, but there is a growing shift toward premium office space in core business districts, especially among financial, professional services, and high-tech sectors. Return-to-office policies are further along compared to other global markets, with hybrid models giving way to more structured, on-site work requirements. Occupiers are seeking environments that enhance collaboration, innovation, and talent retention – particularly in Shanghai, Beijing, and Shenzhen, where talent competition remains intense. 'Occupiers in China are increasingly focused on quality—not just in location and amenities, but in how the workplace supports business strategy and employee wellbeing,' said Jonathan Wei, Head of Project and Occupier Services, China at Cushman & Wakefield. 'Landlords who can deliver integrated, experience-driven environments with flexible, tech-enabled solutions are strongly positioned to attract and retain long-term tenants.'
Malaysian Reserve
14 hours ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
